Harbour Capital Advisors LLC Acquires 86 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Harbour Capital Advisors LLC increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% in the third quarter, HoldingsChannel.com reports. The fund owned 6,286 shares of the pharmaceutical company’s stock after acquiring an additional 86 shares during the period. Harbour Capital Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $2,942,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Capital World Investors raised its stake in Vertex Pharmaceuticals by 17.2% in the first quarter. Capital World Investors now owns 25,567,184 shares of the pharmaceutical company’s stock worth $10,687,339,000 after buying an additional 3,761,414 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Vertex Pharmaceuticals by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 22,676,518 shares of the pharmaceutical company’s stock worth $9,479,011,000 after acquiring an additional 394,338 shares during the period. Capital Research Global Investors raised its position in shares of Vertex Pharmaceuticals by 61.0% in the 1st quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company’s stock worth $2,401,000,000 after acquiring an additional 2,176,218 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of Vertex Pharmaceuticals by 21.2% in the 1st quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company’s stock valued at $1,999,080,000 after purchasing an additional 837,461 shares during the period. Finally, Janus Henderson Group PLC boosted its position in shares of Vertex Pharmaceuticals by 10.4% during the first quarter. Janus Henderson Group PLC now owns 2,584,315 shares of the pharmaceutical company’s stock valued at $1,080,296,000 after purchasing an additional 244,336 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 15,202 shares of the stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $497.00, for a total value of $7,555,394.00. Following the transaction, the chief executive officer now directly owns 106,172 shares in the company, valued at approximately $52,767,484. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the company’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $488.46, for a total value of $1,113,688.80. Following the completion of the transaction, the chief marketing officer now directly owns 25,539 shares in the company, valued at $12,474,779.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Reshma Kewalramani sold 15,202 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $497.00, for a total transaction of $7,555,394.00. Following the sale, the chief executive officer now owns 106,172 shares in the company, valued at $52,767,484. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,487 shares of company stock worth $14,657,149. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $498.73 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. Vertex Pharmaceuticals Incorporated has a 1 year low of $341.90 and a 1 year high of $510.64. The company has a market cap of $128.72 billion, a P/E ratio of -245.68 and a beta of 0.40. The stock’s fifty day moving average price is $474.92 and its 200-day moving average price is $459.08.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The firm had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same period in the previous year, the business posted $3.53 earnings per share. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on VRTX shares. Scotiabank assumed coverage on Vertex Pharmaceuticals in a report on Wednesday. They issued a “sector perform” rating and a $480.00 price objective for the company. UBS Group boosted their price objective on shares of Vertex Pharmaceuticals from $477.00 to $562.00 and gave the stock a “buy” rating in a research note on Thursday. StockNews.com cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 5th. Barclays lowered shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $472.00 to $509.00 in a report on Monday, August 5th. Finally, Canaccord Genuity Group upped their price target on Vertex Pharmaceuticals from $371.00 to $376.00 and gave the stock a “sell” rating in a research note on Wednesday, July 31st. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $492.92.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.